Ethicon Energy announces launch of articulating laparoscopic energy device in US

11 November 2013 (Last Updated November 11th, 2013 18:30)

Ethicon Endo-Surgery (Ethicon), part of the Johnson & Johnson group of companies, has announced that its first-to-market Enseal G2 articulating tissue sealer is now available in the US.

enseal

Ethicon Endo-Surgery (Ethicon), part of the Johnson & Johnson group of companies, has announced that its first-to-market Enseal G2 articulating tissue sealer is now available in the US.

Enseal G2 articulating tissue sealer is a bipolar energy device that allows surgeons to take a perpendicular approach to seal vessels up to 7mm in diameter through a 5mm port.

The Enseal G2 articulating can make manoeuvring easier, provide better access to tissue in deep or tight spaces, and improve control of the angle of approach to vessels.

It allows surgeons to take a perpendicular approach to vessel sealing, which contributes to stronger seals when compared with Enseal non-articulating devices.

The device also increases surgeon's ability to take the full vessel in a single bite by reducing the likelihood of internal bleeding and post-surgery complications in patients.

The 'Perpendicular Blood Vessel Sealing in Surgical Practice' white paper, a cross-specialty collaboration between Dr Andrew I Brill, and Dr Michael J Stamos, concludes that in certain procedures 'technical accuracy and the security of vessel sealing are best accomplished using a perpendicular approach for the clarification of key anatomy and the optimal use of advanced bipolar electrosurgery'.

According to the company, the vessels sealed with a perpendicular approach using Enseal G2 Articulating are more than 28% stronger than vessels sealed at a 45° angle.

"The vessels sealed with a perpendicular approach using Enseal G2 Articulating are more than 28% stronger than vessels sealed at a 45° angle."

Iowa Methodist oncologist Dr Steven A Elg said: "The ENSEAL G2 articulating allowed me to perform the entire para-aortic dissection from the same port. Prior to ENSEAL articulation this was not possible."

The company said that the new device builds on the benefits of its existing portfolio of advanced bipolar tissue sealers.

In February, the company received US Food and Drug Administration (FDA) 510(k) clearance.

The new device will be featured at the 42nd American Association of Gynecologic Laparoscopists (AAGL) Global Congress on Minimally Invasive Gynecology.

According to GlobalData estimates, the US electrosurgical devices market was valued at $428m in 2012 and is expected to grow at a CAGR of 5.2% to reach $609m by 2019.


Image: Enseal G2 articulating on tissue. Photo: courtesy of Business Wire/Ethicon Endo-Surgery.